pavurutamab

AMG 701 (pavurutamab) is an investigational, half-life extended bispecific T-cell engager (BiTE) antibody designed to target B-cell maturation antigen (BCMA) on multiple myeloma cells and CD3 antigen on T cells. By binding both BCMA and CD3, AMG 701 redirects cytotoxic T lymphocytes to lyse BCMA-expressing tumor cells through T-cell–dependent cellular cytotoxicity. The drug was developed for the treatment of relapsed or refractory multiple myeloma (RRMM), particularly in patients who had received multiple prior lines of therapy. Preclinical studies demonstrated potent anti-myeloma activity, including in patient-derived samples resistant to other therapies, and synergy with immunomodulatory drugs such as lenalidomide and pomalidomide. Clinical trials showed promising response rates; however, development was discontinued for strategic reasons despite encouraging efficacy data[1][2][4][5][8].

Other names

pavurutamab